Table of Contents
A patent portfolio analysis Boston founders and general counsel rely on has to reckon with a fact that sets this city apart from every other U.S. tech hub: most of the invention started inside a university lab. Boston and Cambridge form the densest life-sciences cluster on earth, and the patents that anchor a local estate were often filed by MIT, Harvard or a hospital, licensed out under Bayh-Dole, and now carry government-funding strings that a Silicon Valley portfolio never touches. Add a biologics lifecycle measured in decades, patent-term extension math, and a District of Massachusetts that now runs patent cases on a fixed calendar, and the analysis looks nothing like a coastal software audit.
Why a patent portfolio analysis Boston company needs starts at the university
In most cities you can read a company’s patent estate as a self-contained asset. In Boston you usually cannot, because the foundational patents were born in an academic lab and reached the company through a license. The Broad Institute, founded jointly by MIT and Harvard in 2003, MIT’s Technology Licensing Office and Harvard’s Office of Technology Development are among the most prolific patent owners in the region, and their inventions seed a steady stream of Kendall Square start-ups.
That origin changes the first question the analysis has to ask. It is not only “what does the company own,” but “what does the company actually control, and on what terms.” A Boston estate is frequently a stack of in-licensed university patents, sublicenses, field-of-use carve-outs and improvement patents layered on top. Reading title alone will mislead you.
So a genuine patent portfolio analysis Boston teams commission maps the chain of title and the license terms first: which patents are owned outright, which are exclusively licensed from a university, what fields and territories the license covers, and where the improvements sit. Get that wrong and every downstream valuation, freedom-to-operate call and financing representation inherits the error.
Bayh-Dole obligations that ride along with a Kendall Square estate
Because so many Boston patents trace back to federally funded academic research, the Bayh-Dole Act of 1980 is a live part of the analysis, not a footnote. Bayh-Dole let universities keep title to inventions made with federal money, which is precisely what built the Kendall Square ecosystem. But it attaches conditions that travel with the patent through every license and sublicense.
The obligations are concrete. The funding agency keeps a nonexclusive, worldwide government-use license. Exclusive licensees of a pharmaceutical or medical product must substantially manufacture in the United States absent a waiver. Disclosure and election-of-title deadlines must have been met, and a defective disclosure can cloud title years later. A confirmatory license to the government should appear in the record.
Then there are march-in rights, which let an agency compel licensing if an invention is not made available on reasonable terms. They have never been exercised in the 45 years of the statute, yet in August 2025 the Department of Commerce notified Harvard that it intended to begin the march-in process over alleged Bayh-Dole non-compliance. For any Boston portfolio built on university patents, verifying Bayh-Dole compliance is now due diligence, not paranoia.
The biologics lifecycle: PTE, exclusivities and the BPCIA clock
Boston’s estates are disproportionately biologics, small molecules and gene therapies, and those assets live on a very long, very regulated clock. A portfolio analysis that treats a drug patent like a software patent will misjudge both its remaining life and its real value.
The first lever is patent-term extension under 35 U.S.C. 156, which restores time a patent lost while the product sat in FDA review. PTE can add up to five years, but only one patent may be extended per regulatory review period, so the analysis has to identify which single patent in the family is the right candidate and confirm the eligibility windows. Getting the PTE election wrong can quietly forfeit years of exclusivity.
The second lever is the biosimilar landscape under the Biologics Price Competition and Innovation Act. The BPCIA’s “patent dance” forces a structured exchange that narrows which patents a reference sponsor can assert against a biosimilar applicant. A Boston biologics portfolio therefore has to be read as two estates at once: the composition and manufacturing patents, and the method-of-treatment patents that dictate how the therapy is used and defended.
Mapping the estate: what a rigorous portfolio analysis delivers
With the local context set, the mechanical work is the same discipline we apply everywhere, tuned to Boston’s science. We inventory every asset, then cluster the patents by the technology and the product they protect so that management can see the estate the way a competitor or an acquirer will.
A thorough review typically produces:
- A verified inventory with legal status, owner, assignee and remaining term for each family
- Chain-of-title and license mapping, flagging every in-licensed university patent and its field-of-use limits
- A Bayh-Dole compliance check on all federally funded inventions
- Claim-scope clustering that shows which products each family actually covers
- PTE and exclusivity timelines for regulated products, family by family
- Gaps, white space and abandonment candidates ranked by strategic value
The output is not a spreadsheet dump. It is a decision tool that tells a Boston board which patents to keep paying maintenance fees on, which to license out, which to challenge in a rival’s estate, and where the next filing should go before a competitor gets there.
Litigation and validity: reading a portfolio for the District of Massachusetts
A portfolio is only as strong as it is when tested, so the analysis has to anticipate enforcement and attack. Patent suits filed in Boston go to the U.S. District Court for the District of Massachusetts at the John Joseph Moakley U.S. Courthouse on the Fan Pier waterfront, completed in 1999. Unlike some general-litigation districts, D. Mass. adopted local patent rules effective 1 June 2018 that impose a real timetable.
Those rules matter to how you read an estate. The court aims to hold the claim-construction (Markman) hearing within nine months of the initial scheduling conference and to reach trial within about two years. That compressed calendar rewards the party that already knows, before filing, which claims are strongest and which are exposed. Appeals, as from every district, run not to the First Circuit but to the U.S. Court of Appeals for the Federal Circuit.
Validity is the other half of the read. Any asserted claim can be challenged at the Patent Trial and Appeal Board through inter partes review, and life-sciences patents also face written-description and enablement attacks. We connect portfolio work to a full prior art & litigation search and, where the risk runs the other way, to a patent invalidation strategy, so the estate is understood from both sides before a complaint is drafted.
Robotics, medtech and the rest of the Boston docket
Life sciences lead, but they are not the whole story, and a Boston portfolio analysis has to handle the region’s other patent-heavy sectors on their own terms. Massachusetts is a global robotics hub: Boston Dynamics, an MIT spin-off founded in 1992 and now owned by Hyundai, and iRobot, maker of the Roomba, both grew out of MIT labs, and MassRobotics has anchored the cluster since 2015.
Robotics and medtech estates read differently from biologics. Value concentrates in systems-and-methods claims covering perception, actuation, control software and human-machine interaction, where divided infringement and Section 101 eligibility questions attach, and where design patents and trade secrets often sit alongside the utility patents. The analysis has to weigh all four forms of protection together.
The academic thread runs through these sectors too. A robotics or device company spun out of MIT, Harvard, Northeastern or Boston University frequently holds in-licensed university patents with the same Bayh-Dole strings as a biotech, so the chain-of-title and government-rights review is just as essential outside the drug world as inside it.
How we work with Boston founders, counsel and investors
Most Boston engagements reach us at an inflection point: a Series B or crossover round, a licensing negotiation with a university, a potential acquisition, or a competitor’s assertion. Each needs the same foundation, an honest map of what the company owns, controls and is exposed to, delivered fast enough to inform the decision at hand.
We work from the patents and published applications, the license and sponsored-research agreements, USPTO and PAIR records, FDA submissions and labels for regulated products, and the peer-reviewed literature that Boston’s researchers publish openly. For diligence we deliver a representations-ready view of the estate; for strategy we deliver a prioritized filing, pruning and licensing plan.
Boston runs on Eastern Time inside the U.S. business day, so work coordinated with D. Mass. counsel, university technology-transfer offices, or PTAB teams in Washington moves within a single cycle. The aim of every patent portfolio analysis Boston companies ask us for is the same: a clear, defensible picture of the estate that a board, an investor or a court can act on without a translator.
IP Landscape & Resources in Boston
Key intellectual-property authorities and venues relevant to Boston:
- United States Patent and Trademark Office — grants U.S. patents and maintains the assignment and file-history records that anchor any portfolio inventory and chain-of-title review
- USPTO — Patent Trial and Appeal Board — decides inter partes review and other validity challenges that can cancel claims in a portfolio, making validity central to the analysis
- U.S. District Court for the District of Massachusetts — the federal court at the John Joseph Moakley U.S. Courthouse in Boston whose 2018 local patent rules set the timetable for enforcement
- U.S. Court of Appeals for the Federal Circuit — hears all patent appeals from the District of Massachusetts and the PTAB, giving both tracks a single appellate forum
Request a Patent Portfolio Analysis Review in Boston
Request a Patent Portfolio Analysis Review in Boston
Send us your patent list, your university and sponsored-research licenses, and the decision you are facing, whether a raise, a deal or a dispute. We will map the estate, check Bayh-Dole and PTE exposure, and flag the strongest and weakest assets, with cost and turnaround confirmed before any work begins.
Explore related PerspireIP services: Patent Portfolio Analysis · IP monetization · prior art & litigation search · patent invalidation · our United States IP hub.
Frequently Asked Questions
Why is a patent portfolio analysis in Boston different from one in San Francisco?
Because most Boston patents originate in university labs. MIT’s Technology Licensing Office, Harvard’s Office of Technology Development, the Broad Institute and Boston hospitals are among the region’s biggest patent owners, so a local estate is usually a stack of in-licensed academic patents carrying Bayh-Dole obligations, not the self-owned software patents typical of a Bay Area company.
What Bayh-Dole issues affect a Kendall Square biotech portfolio?
Federally funded university inventions carry conditions that travel with the patent: a government-use license, U.S.-manufacturing preference for exclusive licensees, disclosure and election deadlines, and march-in rights. Those rights have never been exercised, but in August 2025 the Commerce Department moved to begin the march-in process against Harvard, so verifying Bayh-Dole compliance is now core diligence for any Boston estate.
How does patent-term extension factor into a Boston drug portfolio?
Patent-term extension under 35 U.S.C. 156 restores time a patent lost during FDA review and can add up to five years. Only one patent may be extended per regulatory review period, so the analysis identifies the single best candidate in each family and confirms eligibility, because a wrong election can silently forfeit years of exclusivity on a Boston biologic.
Which court hears a patent case involving a Boston company?
The U.S. District Court for the District of Massachusetts, at the John Joseph Moakley U.S. Courthouse on Boston’s Fan Pier waterfront. Its 2018 local patent rules aim for a Markman hearing within nine months and trial within about two years. Appeals go to the Federal Circuit, not the First Circuit, so the governing claim construction is the Federal Circuit’s.
Do robotics and medtech portfolios in Boston need the same review?
Yes, but with a different emphasis. Boston Dynamics, iRobot and the MassRobotics cluster produce estates where value sits in systems-and-methods claims, design patents and trade secrets, with Section 101 and divided-infringement questions in play. Many of these companies also spun out of MIT or Harvard, so the same Bayh-Dole and chain-of-title review applies outside the drug world.
When should a Boston company commission a portfolio analysis?
Before a financing round, a university licensing negotiation, an acquisition, or a competitor’s assertion. Each turns on an honest map of what the company owns, controls and is exposed to. We deliver a representations-ready estate view for diligence and a prioritized filing, pruning and licensing plan for strategy, coordinated within the U.S. business day.